Verve Therapeutics (NASDAQ:VERV - Get Free Report)'s stock had its "neutral" rating reaffirmed by analysts at HC Wainwright in a report released on Wednesday,Benzinga reports. They currently have a $13.50 price target on the stock. HC Wainwright's price target would suggest a potential upside of 18.63% from the stock's current price.
Other equities research analysts also recently issued reports about the stock. Royal Bank Of Canada lowered their target price on shares of Verve Therapeutics from $17.00 to $15.00 and set an "outperform" rating for the company in a report on Tuesday, March 4th. Canaccord Genuity Group cut shares of Verve Therapeutics from a "strong-buy" rating to a "hold" rating and reduced their price target for the company from $39.00 to $13.00 in a research report on Tuesday. Guggenheim lifted their price target on shares of Verve Therapeutics from $18.00 to $24.00 and gave the company a "buy" rating in a research report on Tuesday, April 15th. Cantor Fitzgerald raised shares of Verve Therapeutics from a "neutral" rating to an "overweight" rating in a research report on Tuesday, April 15th. Finally, William Blair cut shares of Verve Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Tuesday. Six equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $14.75.
Get Our Latest Stock Report on VERV
Verve Therapeutics Stock Performance
Verve Therapeutics stock opened at $11.38 on Wednesday. Verve Therapeutics has a 1 year low of $2.86 and a 1 year high of $11.41. The firm has a 50 day moving average price of $5.02 and a 200 day moving average price of $5.84. The company has a market cap of $1.01 billion, a price-to-earnings ratio of -5.39 and a beta of 1.67.
Verve Therapeutics (NASDAQ:VERV - Get Free Report) last released its earnings results on Wednesday, May 14th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.71) by $0.36. Verve Therapeutics had a negative net margin of 303.64% and a negative return on equity of 35.81%. The firm had revenue of $32.98 million during the quarter, compared to the consensus estimate of $7.13 million. Sell-side analysts predict that Verve Therapeutics will post -2.49 EPS for the current year.
Institutional Trading of Verve Therapeutics
Institutional investors have recently added to or reduced their stakes in the stock. ProShare Advisors LLC raised its holdings in Verve Therapeutics by 30.4% in the fourth quarter. ProShare Advisors LLC now owns 24,016 shares of the company's stock valued at $135,000 after acquiring an additional 5,592 shares in the last quarter. Norges Bank acquired a new stake in Verve Therapeutics in the fourth quarter valued at $441,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Verve Therapeutics by 16.5% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 144,749 shares of the company's stock valued at $816,000 after acquiring an additional 20,483 shares in the last quarter. Wells Fargo & Company MN raised its holdings in Verve Therapeutics by 25.0% in the fourth quarter. Wells Fargo & Company MN now owns 45,422 shares of the company's stock valued at $256,000 after acquiring an additional 9,083 shares in the last quarter. Finally, BNP Paribas Financial Markets acquired a new stake in Verve Therapeutics in the fourth quarter valued at $50,000. 97.11% of the stock is owned by institutional investors and hedge funds.
Verve Therapeutics Company Profile
(
Get Free Report)
Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Verve Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Verve Therapeutics wasn't on the list.
While Verve Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
